#USA #Providence #EpiVax #ISPRI toolkit #PANDA Screening

A Year of Innovation: EpiVax in 2024

EpiVax, Inc., a forefront player in the realm of immunogenicity risk assessment for biologics and peptide therapeutics, is celebrating a year of significant advancements and remarkable growth in 2024. Established as a leader in preclinical assessments, EpiVax's strategic efforts this year have emphasized scientific innovation, service diversification, and an impressive corporate expansion.

This year, the company's flagship ISPRI™ (Immunogenicity Screening and Protein Re-engineering Interface) Toolkit has seen substantial upgrades. EpiVax introduced an array of new service capabilities that cater to varied stages of preclinical development. The launch of fee-for-service analyses through ISPRI Downselect™, Quantify™, Analyze™, Evaluate™, Complete™, Optimize™, and Design™ empowers developers by enabling them to effectively rank candidates, conduct modality-specific benchmarking, optimize sequences, and perform in-depth risk analyses with increased accuracy. Additionally, the introduction of Class I analysis to the ISPRI toolkit has been a pivotal enhancement, specifically for select gene therapy and CAR-T clients.

EpiVax's commitment to retaining its market leadership can be recognized in the evolution of its PANDA® Screening program. Designed to facilitate sponsors' navigation through the FDA's Abbreviated New Drug Application (ANDA) pathway for generic peptides and their impurities, the program has seen key updates. Enhanced adaptive in vitro assay offerings and the introduction of the Innate Immune Response Assay reinforce EpiVax's position as the ultimate resource for generic drug developers, providing comprehensive support through in silico, in vitro, and innate assessments under one roof.

In collaboration with the FDA, EpiVax embarked on a new contract aimed at establishing standardized controls for T cell assays. This initiative aims to enhance the specificity and sensitivity of such assays across the industry, showcasing EpiVax's contribution to setting higher standards in immunogenicity assessment.

The achievements of 2024 have not gone unnoticed, as EpiVax witnessed a staggering nearly 60% increase in immunogenicity risk assessment bookings compared to the previous year. This growth was fueled by a doubling of new clientele across its ISPRI™ Access, ISPRI™ Fee-for-Service, and PANDA® service segments. Consequently, the company expanded its workforce by 18%, integrating new strategic leadership to propel growth and explore new offerings further.

As EpiVax anticipates the challenges and opportunities of 2025, it remains rooted in its philosophy of 'fearless science.' Plans are underway to enhance existing platforms by integrating advanced artificial intelligence and machine learning capabilities, enlarging lab capacities, and augmenting scientific expertise. These developments will be officially announced in the upcoming year, promising more significant innovation in the immunogenicity and biological therapeutic realms.

About EpiVax

EpiVax is at the forefront of preclinical immunogenicity assessment and sequence optimization, specializing in peptide therapeutics, biologic therapeutics, and vaccines. Collaborating with global companies, agencies, and academic institutions, EpiVax is dedicated to accelerating immunogenicity risk assessment while pioneering immune modulation and rapid vaccine design. For more details, visit EpiVax's official site.